| 07/10/2015 | ||
 7:30 am - 8:00 am | Registration Pre-Function Area | |
| 8:00 am - 10:30 am | Opening Ceremony and Session A: Epidemiology and transmission of HCV infection The Grand Ballroom One Chairperson: Dr Joseph Doyle, Burnet Institute, Australia and Eliot Ross Albers, International Network of People Who Use Drugs | |
| 8:00 am - 8:10 am | Welcome to Country The Grand Ballroom One | |
| 8:10 am - 8:20 am | Introduction to the Conference The Grand Ballroom One Associate Professor Jason Grebely, UNSW | |
| 8:20 am - 8:30 am | Opening from Community Member The Grand Ballroom One Annie Madden, Australian Injecting and Illicit Drug Users League (AIVL) | |
| 8:30 am - 8:50 am | Epidemiological definitions and estimates of populations of PWID with HCV infection The Grand Ballroom One Dr Sarah Larney, UNSW Presentation | |
| 8:50 am - 9:10 am | Emerging drug patterns and HCV transmission: An increasing cause for concern The Grand Ballroom One Professor Julie Bruneau, University of Montreal | |
| 9:10 am - 9:30 am | Molecular epidemiology of HCV among PWID: New insights into HCV transmission The Grand Ballroom One Professor Mel Krajden, British Columbia Centre for Disease Control and University of British Columbia Presentation | |
| 9:30 am - 9:45 am | Impact of Opiate Substitution Therapy and Needle Syringe Programmes on Incidence of HCV: A Systematic Review and Meta-Analysis The Grand Ballroom One Lucy Platt, London School of Hygiene and Tropical Medicine | |
| 9:45 am - 10:00 am | Characterising Hepatitis C Virus Transmission Dynamics in a High-Risk Incarcerated Population The Grand Ballroom One Neil Bretana, UNSW Presentation | |
| 10:00 am - 10:15 am | Drawing Them In – Stories from People Who Know The Grand Ballroom One Heather McCormack, Hepatitis NSW | |
| 10:15 am - 10:30 am | HCV Treatment and Prevention: What is the Impact of Current and Scaled-Up Treatment Rates in Selected Sites in Europe? The Grand Ballroom One Hannah Woodall, University of Bristol | |
| 10:30 am - 11:00 am | Morning Tea Exhibition Hall | |
| 11:00 am - 12:45 pm | Session B: Prevention and Treatment for HCV: From modelling to implementation The Grand Ballroom One Chairperson: Associate Professor Natasha Martin, University of California San Diego Chairperson: Annie Madden, Australian Injecting and Illicit Drug Users League (AIVL) | |
| 11:00 am - 11:15 am | Strategies for the prevention of HCV infection The Grand Ballroom One Professor Lisa Maher, UNSW | |
| 11:15 am - 11:30 am | Prevention and Treatment for HCV: From modelling to implementation The Grand Ballroom One Professor Matthew Hickman, University of Bristol Presentation | |
| 11:30 am - 11:45 am | HCV Treatment and Prevention in the Community - the Treatment and Prevention (TAP) study The Grand Ballroom One Professor Margaret Hellard, The Burnet Institute Presentation | |
| 11:45 am - 12:00 pm | HCV Treatment and Prevention in the Prison - the Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) Study The Grand Ballroom One Professor Andrew Lloyd, UNSW Presentation | |
| 12:00 pm - 12:15 pm | The needs of PWID in the future of HCV care: Implications for treatment as prevention The Grand Ballroom One Dr Magdalena Harris, London School of Hygiene and Tropical Medicine Presentation | |
| 12:15 pm - 12:45 pm | Panel Discussion The Grand Ballroom One | |
| 12:45 pm - 2:15 pm | Lunch Exhibition Hall | |
| 12:45 pm - 2:15 pm | Satellite Symposium - Abbvie The Grand Ballroom | |
| 2:15 pm - 3:30 pm | Session C: Oral Abstracts HCV Epidemiology, Public Health and Modelling The Grand Ballroom One Chairperson: Peter Vickerman, University of Bristol Chairperson: Mary Harrod, NSW Users and AIDS Association | Session D: Oral Abstracts Social and Community Research The Grand Ballroom Two Chairperson: Dr Magdalena Harris, London School of Hygiene and Tropical Medicine Chairperson: Leona Quewezance, All Nations Hope Network |
| 2:15 pm - 2:30 pm | Onward Transmission of Hepatitis C Virus Infection among Younger and Older People who Inject Drugs in Vancouver, Canada The Grand Ballroom One Brendan Jacka, The Kirby Institute, UNSW Australia Abstract | The Next Step in Collaborative HCV Care - PWID, Partnerships and Potential to Treat The Grand Ballroom Two Jenny Bourke, Hepatitis C Community Clinic Abstract |
| 2:30 pm - 2:45 pm | Network-Based Modeling for HCV in US Drug Injectors: Treatment as Prevention The Grand Ballroom One Alexei Zelenev, Yale School of Medicine Abstract | Experiences of PWID Community Network in Linking HCV Testing and Care to Treatment Using Direct Acting Antivirals The Grand Ballroom Two Nalinikanta Rajkumar, Community Network for Empowerment (CoNE) Abstract |
| 2:45 pm - 3:00 pm | The Hepatitis C Epidemic Amongst Men who have Sex with Men: Modelling the Role of Behavioural Risk Heterogeneity and HIV Dependent Mixing Patterns The Grand Ballroom One Louis MacGregor, University of Bristol Abstract | Will the Moment of Hepatitis C Diagnosis Undermine the Promise of New Treatments? An Analysis of Canadian Women's Experiences The Grand Ballroom Two Sandi Mitchell, University of Sydney AbstractPresentation |
| 3:00 pm - 3:15 pm | Liver Disease Knowledge and Acceptability of Non-Invasive Liver Fibrosis Assessment among People who Inject Drugs in the Drug and Alcohol Setting: The Liverlife Study The Grand Ballroom One Alison Marshall, Kirby Institute AbstractPresentation | “It’s Not Only My Life I Got to Worry About”: Accounts of Needle-Syringe Sharing and Negotiated Safety among Couples who Inject Drugs The Grand Ballroom Two Jake Rance, Centre for Social Research in Health Abstract |
| 3:15 pm - 3:20 pm | Female to Male Ratio of Hepatitis C Virus Incidence; A Systematic Review and Meta Analysis The Grand Ballroom One Aryan Esmaeili, Icahn School of Medicine at Mount Sinai Abstract | Hepatitis See – Low Literacy Hepatitis C Guide for People who Inject Drugs The Grand Ballroom Two Clare Mannion, cohealth Diana Macdonald, Alfred Health Abstract |
| 3:20 pm - 3:25 pm | Relational and Contingent Risk and Harm Reduction: Blood-Borne Virus Prevention and Care in an Urban, Culturally Diverse Neighbourhood The Grand Ballroom One Elizabeth Peach, Burnet Institute Abstract | Empowering Conscious Health Consumers in an Changing Treatment Landscape The Grand Ballroom Two Kyle Leadbeatter, Hepatitis NSW AbstractPresentation |
| 3:25 pm - 3:30 pm | HCV Diagnostic Screening among People who Inject Drugs in Australia The Grand Ballroom One Jenny Iversen, The Kirby Institute AbstractPresentation | Making Hepatitis C Treatment a National Priority in Georgia through Drug Users Community Advocacy The Grand Ballroom Two Paata Sabelashvili, Georgian Harm Reduction Network Abstract |
| 3:30 pm - 4:00 pm | Afternoon Tea Exhibition Hall | |
| 4:00 pm - 5:40 pm | Session E: Enhancing Access to Screening and Assessment for HCV infection The Grand Ballroom One Chairperson: Dr Jenny Iversen, The Kirby Institute, UNSW Chairperson: Kim Gates, Northern Territory AIDS and Hepatitis Council, | |
| 4:00 pm - 4:20 pm | Barriers to HCV screening, diagnosis and assessment: A community perspective The Grand Ballroom One Jude Byrne, Australian Injecting and Illicit Drug Users League | |
| 4:20 pm - 4:40 pm | Barriers to access to screening and assessment of HCV from a patient perspective: A review of the qualitative literature The Grand Ballroom One Professor Carla Treloar, UNSW Presentation | |
| 4:40 pm - 5:00 pm | Interventions to enhance testing and diagnosis of HCV infection among PWID The Grand Ballroom One Professor David Goldberg, Glasgow Caledonian University, Presentation | |
| 5:00 pm - 5:20 pm | Diagnosis and treatment of acute HCV infection in the IFN-free era: Does it really matter? The Grand Ballroom One Professor Gail Matthews, UNSW Presentation | |
| 5:20 pm - 5:40 pm | Non-invasive liver fibrosis assessment: Opportunities for enhanced liver disease assessment and treatment in the drug and alcohol setting The Grand Ballroom One Professor Alessio Aghemo, University of Milan Presentation | |
| 6:00 pm - 7:00 pm | Drink Reception Beachside Dojo | |
| 08/10/2015 | ||
| 8:00 am - 8:30 am | Registration Pre-Function Area | |
| 8:30 am - 10:45 pm | Session F: Treatment of Viral Hepatitis The Grand Ballroom One Chairperson: Professor Olav Dalgard, Akershus University Hospital Chairperson: Tracy Swan, Treatment Action Group | |
| 8:30 am - 9:00 am | IFN-free therapy for HCV infection: In search of perfectovir The Grand Ballroom One Associate Professor Jordan Feld, Physician, University of Toronto Presentation | |
| 9:00 am - 9:20 am | Interventions to enhance treatment and adherence to IFN-free HCV therapy among PWID The Grand Ballroom One Professor Alain Litwin, Albert Einstein College of Medicine Presentation | |
| 9:20 am - 9:40 am | Models of care for management of HCV among PWID The Grand Ballroom One Dr Philip Bruggman, Head of internal medicine of Arud, Arud Centres for Addiction Medicine Presentation | |
| 9:40 am - 9:55 am | C-EDGE CO-STAR: Adherence and Drug use in HCV-Infected Persons who Inject Drugs (PWID) on Opioid Agonist Therapy (OAT) receiving Grazoprevir + Elbasvir (GZR/EBR) fixed Dose Combination (FDC) for 12 Weeks The Grand Ballroom One Professor Greg Dore, UNSW Presentation | |
| 9:55 am - 10:10 am | High Rates of Sustained Virological Response in People Who Inject Drugs Treated with Sofosbuvir-Based Regimens The Grand Ballroom One Professor Alain Litwin, Albert Einstein College of Medicine Presentation | |
| 10:10 am - 10:25 am | Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS Study, Australia The Grand Ballroom One Professor Carla Treloar, UNSW Presentation | |
| 10:25 am - 10:40 am | Hepatitis C Reinfection Following Sustained Virological Response – A Seven Year Follow-Up of Norwegian Patients Infected through Injecting Drug Use The Grand Ballroom One Håvard Midgard, Akershus University Hospital Presentation | |
| 10:40 am - 10:45 am | Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs: Special Issues from the International Journal of Drug Policy The Grand Ballroom One Professor Gerry Stimson, London School of Hygiene and Tropical Medicine and Editor, International Journal of Drug Policy Presentation | |
| 10:45 am - 11:15 am | Morning Tea Exhibition Hall | |
| 11:15 am - 12:15 pm | Session G: Debate The Grand Ballroom One Panellist: Professor Matthew Hickman, University of Bristol Panellist: Professor Margaret Hellard, The Burnet Institute Panellist: Karyn Kaplan, Director, International Hepatitis/HIV Policy & Advocacy at Treatment Action Group (TAG) Panellist: Professor Marina Klein, McGill University Health Centre Panellist: Andrew Hill, Liverpool University Panellist: Annie Madden, Australian Injecting and Illicit Drug Users League (AIVL) Moderator: Professor Carla Treloar, UNSW | |
| 12:15 pm - 1:45 pm | Lunch Exhibition Hall | |
| 12:15 pm - 1:45 pm | Satellite Symposium - Gilead The Grand Ballroom | |
| 1:45 pm - 3:00 pm | Session H: Oral Abstracts HCV treatment and management The Grand Ballroom One Chairperson: Dr John Dillon, University of Dundee Chairperson: Fiona Poeder, NSW Users and AIDS Association | Session I: Oral Abstracts HCV Epidemiology and Screening The Grand Ballroom Two Chairperson: Professor Gerry Stimson, London School of Hygiene and Tropical Medicine and Editor, International Journal of Drug Policy Chairperson: Charles Henderson, New Zealand Needle Exchange Programme |
| 1:45 pm - 2:00 pm | Efficacy of Response-Guided Pegylated Interferon and Ribavirin Therapy for People who Inject Drugs with HCV Genotype 2/3 Infection: The ACTIVATE Study The Grand Ballroom One Jason Grebely, The Kirby Institute, UNSW Australia AbstractPresentation | Hepatitis C Treatment Uptake among Patients Receiving Opioid Substitution Treatment: A Population Based Study The Grand Ballroom Two Håvard Midgard, Akershus University Hospital AbstractPresentation |
| 2:00 pm - 2:15 pm | Evaluation of Treatment of HCV Infection in Active Injection Drug Users The Grand Ballroom One Arshia Alimohammadi, Vancouver Infectious Diseases Centre Abstract
| Changes in Injection Drug Use among Recently Hepatitis C Virus-Infected Persons who Inject Drugs Offered Treatment in Montreal, Canada The Grand Ballroom Two Andreea Adelina Artenie, Université de Montréal AbstractPresentation
|
| 2:15 pm - 2:30 pm | How should HCV Antiviral Treatment be Prioritized in the Direct-Acting Antiviral Era? An Economic Evaluation including Individual and Population Prevention Benefits The Grand Ballroom One Natasha Martin, University of California San Diego Abstract | The Potential Prevention Impact of Scaling Up Hepatitis C Virus Treatment for People who Inject Drugs in Prison: A Modeling Analysis for Scotland The Grand Ballroom Two Jack Stone, University of Bristol Abstract
|
| 2:30 pm - 2:45 pm | Hepatitis C Treatment for People who Inject Drugs: Are Direct-Acting Antivirals Cost-Effective? The Grand Ballroom One Daniela van Santen, Public Health Service of Amsterdam AbstractPresentation | Modelling the Impact of a National Scale Up of Interventions on Hepatitis C Virus Transmission among People who Inject Drugs in Scotland The Grand Ballroom Two Hannah Woodall, University of Bristol Abstract |
| 2:45 pm - 2:50 pm | Pilot Study: Combining Formal and Peer Education with Fibroscan to Increase HCV Screening and Treatment in Persons Who Inject Drugs The Grand Ballroom One Amber Arain, Hasselt University AbstractPresentation | Factors Associated with Undiagnosed Hepatitis C Infection among People who Inject Drugs: Missed Opportunities for Diagnostic Testing in The United Kingdom (UK) The Grand Ballroom Two Vivian Hope, Public Health England AbstractPresentation |
| 2:50 pm - 2:55 pm | A Single Tablet Regimen of Ledipasvir + Sofosbuvir is Efficacious and Well-Tolerated Among People Receiving Opiate Substitution Therapy The Grand Ballroom One Jason Grebely, The Kirby Institute, UNSW Australia AbstractPresentation | Trends in End-Stage Liver Disease among People Receiving Opioid Substitution Therapy with an HCV Notification in New South Wales, Australia between 1993 and 2012 The Grand Ballroom Two Reem Waziry, Kirby-UNSW AbstractPresentation |
| 2:55 pm - 3:00 pm | Is Increased HCV Case-Finding Combined With 8-12 Week Interferon-Free Direct-Acting Antiviral Treatment Cost-Effective in UK Prisons? A Dynamic Cost Utility Analysis including Treatment as Prevention Benefits The Grand Ballroom One Natasha Martin, University of California San Diego Abstract | The Community Pop-Up Clinic as a Tool of Engagement for Vulnerable Populations with HCV and HIV Infection The Grand Ballroom Two Syune Hakobyan, Vancouver ID Research and Care Centre Society AbstractPresentation |
| 3:00 pm - 3:30 pm | Afternoon Tea Exhibition Hall | |
| 3:30 pm - 5:10 pm | Session J: Important issues for the management HCV among PWID The Grand Ballroom One Chairperson: Professor Geert Robaeys, Ziekenhuis Oost Limburg | |
| 3:30 pm - 3:40 pm | The Change Project: International stories of PWID with HCV who have received interferon-free treatment The Grand Ballroom One | |
| 3:40 pm - 4:00 pm | A national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia The Grand Ballroom One Professor Mojca Maticic, University Medical Centre, Ljubljana Presentation | |
| 4:00 pm - 4:20 pm | Peer support for HCV infection: The potential for transformation in the drug and alcohol setting The Grand Ballroom One Sione Crawford, Canberra Alliance for Harm Minimisation and Advocacy Presentation | |
| 4:20 pm - 4:40 pm | The Hep C European Initiative: Integrating research, practice and policy The Grand Ballroom One Eberhard Schatz, Correlation Network, Amsterdam Presentation | |
| 4:40 pm - 5:00 pm | Epidemiology of HCV reinfection and mixed infection in the treatment setting The Grand Ballroom One Dr Janke Schinkel, Academic Medical Center of the University of Amsterdam Presentation | |
| 5:00 pm - 5:20 pm | Management of HCV/HIV co-infection in the IFN-free era The Grand Ballroom One Professor Marina Klein, McGill University Health Centre | |
| 7:00 pm - 11:00 pm | Conference Dinner Taronga Zoo | |
| 09/10/2015 | ||
| 8:00 am - 8:30 am | Registration Pre-Function Area | |
| 8:30 am - 10:30 am | Session K: HCV Diagnostics and Therapeutics: Where are we now and where are we going The Grand Ballroom One Chairperson: Dr Philip Bruggman, Head of internal medicine of Arud, Arud Centres for Addiction Medicine Chairperson: Paata Sabelashvili, Georgian Harm Reduction Network | |
| 8:30 am - 9:00 am | Will HCV therapies deliver global impact? The Grand Ballroom One Professor Greg Dore, UNSW Presentation | |
| 9:00 am - 9:20 am | HCV diagnostics and non-invasive liver disease assessments: What are the current tools in the toolbox and where to from here? The Grand Ballroom One Professor Karine Lacombe, Hospital Saint-Antoine, Paris Presentation | |
| 9:20 am - 9:40 am | Strategies for rolling out testing and treatment for PWID: Evidence from the Ukraine The Grand Ballroom One Ludmila Maistat, Senior Programme Manager, International HIV/AIDS Alliance Presentation | |
| 9:40 am - 10:00 am | Strategies for rolling out harm reduction, and HCV and HBV testing among PWID: Evidence from East Africa The Grand Ballroom One Dr Zin Mar Han, Medecins du Monde-France | |
| 10:00 am - 10:30 am | Morning Tea Exhibition Hall | |
| 10:30 am - 1:00 pm | Session L: Access and implementation for all: Prevention, care and treatment The Grand Ballroom One Chairperson: Professor Matthew Hickman, University of Bristol Chairperson: Nalinikanta Rajkumar, Community Network for Empowerment (CoNE) | |
| 10:30 am - 10:50 am | Access and implementation of IFN-free therapy: where to from here for low and middle income countries The Grand Ballroom One Niklas Luhman, Medicins du Monde Presentation | |
| 10:50 am - 11:10 am | What is the minimum cost to cure Hepatitis C? The Grand Ballroom One Andrew Hill, Liverpool University Presentation | |
| 11:10 am - 11:30 am | Efforts from the community to improve access The Grand Ballroom One Karyn Kaplan, Director, International Hepatitis/HIV Policy & Advocacy at Treatment Action Group (TAG) Presentation | |
| 11:30 am - 11:40 am | The Change Project: Challenges and strategies to enhance HCV testing, linkage to care and HCV treatment among PWID The Grand Ballroom One | |
| 11:40 am - 1:00 pm | Panel Discussion: Challenges and strategies successful for enhancing HCV testing and care among PWID The Grand Ballroom One Chairperson: Professor Margaret Hellard, The Burnet Institute | |
| 1:00 pm - 2:30 pm | Lunch The Grand Ballroom One | |
| 1:00 pm - 2:30 pm | Satellite Symposium - MSD The Grand Ballroom | |
| 2:30 pm - 5:00 pm | Session M: The HCV care package: What should it include and how can we deliver it? The Grand Ballroom One Chairperson: Nicky Bath, NSW Ministry of Health, Chairperson: Fifa Rahmen, Malaysian AIDS Council | |
| 2:30 pm - 2:50 pm | Integrating HCV prevention, care and treatment for PWID: A community perspective The Grand Ballroom One Eliot Ross Albers, International Network of People Who Use Drugs | |
| 2:50 pm - 3:10 pm | Human rights and structural barriers to treatment access The Grand Ballroom One Daniel Wolfe, Open Society Foundation | |
| 3:10 pm - 3:30 pm | WHO guidelines on HCV screening, treatment and care: relevance for PWID The Grand Ballroom One Professor Margaret Hellard, The Burnet Institute | |
| 3:30 pm - 3:45 pm | Session N: Rapporteur Sessions and Conference Closing The Grand Ballroom One | |
| 3:30 pm - 3:45 pm | Report from Community and Advocacy Workshop The Grand Ballroom One Sione Crawford, Canberra Alliance for Harm Minimisation and Advocacy | |
| 3:45 pm - 4:30 pm | Rapporteur report The Grand Ballroom One Associate Professor Jason Grebely, UNSW | |
| 4:30 pm - 4:45 pm | Community Closing Statement The Grand Ballroom One Charles Henderson, New Zealand Needle Exchange Programme | |
| 4:45 pm - 5:00 pm | Conference Closing The Grand Ballroom One Professor Greg Dore, UNSW | |
